CIDR - GENOTYPING SERVICES USING ILLUMINA HUMAN METHYLATION EPIC ARRAY VERSION 2 (BLOOD) ON 1,495 EXPERIMENTAL DNA SAMPLES, NCI, HUANG

CIDR - 使用 ILLUMINA 人类甲基化 EPIC 阵列版本 2（血液）对 1,495 个实验 DNA 样本进行基因分型服务，NCI，HUANG

• 批准号: 10949132
• 负责人: Kimberly F Doheny
• 金额: $ 52.33万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-31 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10949132
• 关键词: CIDR; GENOTYPING; SERVICES; USING; ILLUMINA

Center for Inherited Disease Research (CIDR) Trans-NIH Collaboration The Center for Inherited Disease Research (CIDR) represents an important collaboration between NCI and NHGRI. Since 1996, Institutes of the NIH have participated in the CIDR contract with the Johns Hopkins University. This trans-NIH collaboration is supported by 10 ICs, with NHGRI serving as the lead IC. CIDR provides to NIH-supported grantees state-of-the-art genomics and statistical genetics services, including whole genome and whole exome sequencing, genome-wide association studies (GWAS) and methylation analysis. In addition to providing outstanding genomics services, CIDR also consults on study design and statistical analysis to NIH grantees. A prime reason for continuing this collaboration is that, as a result of the genomics data provided by CIDR, important new insights into genetic diseases/conditions can potentially move a field of research forward. In addition, the data produced by CIDR is required to be deposited in dbGaP so that the data will be available for further analysis by the scientific community at large. All investigators requesting access through the NIH-funded CIDR Program must submit an electronic application to NIH. X01 applications are continuously accepted and are evaluated for scientific merit by the CIDR Access Committee. The CIDR Board of Governors, which is made up of representatives from the supporting ICs, serves as the second level of review and determines which projects are granted access to the CIDR facility. This contract award is to support the Center for Inherited Disease Research (CIDR) project 1X01HG013188-01, Elucidating epigenetic mechanisms of racial/ethnic disparities in pancreatic cancer, specifically for the whole genome genotyping using the Illumina EPIC methylation array of 695 pancreatic cancer cases and 800 age, sex and race/ethniciyy matched controls from the Multi-Ethnic Cohort (MEC). This experiment is for a study to determine whether race/ethnic specific differences in DNA methylation can explain disparities in the risk to develop pancreatic cancer.

遗传疾病研究中心（CIDR）跨NIH合作 遗传疾病研究中心（CIDR）代表了NCI和NHGRI之间的重要合作。 自1996年以来，国家卫生研究院各研究所参加了与约翰霍普金斯大学签订的CIDR合同。这项跨NIH的合作由10个IC支持，NHGRI作为牵头IC。CIDR为NIH支持的受资助者提供最先进的基因组学和统计遗传学服务，包括全基因组和全外显子组测序，全基因组关联研究（GWAS）和甲基化分析。 除了提供出色的基因组学服务外，CIDR还为NIH资助者提供研究设计和统计分析方面的咨询。 继续这种合作的一个主要原因是，由于CIDR提供的基因组学数据，对遗传疾病/病症的重要新见解可能会推动研究领域的发展。 此外，CIDR产生的数据必须存入dbGaP，以便科学界进一步分析。 所有要求通过NIH资助的CIDR项目访问的研究者必须向NIH提交电子申请。 X 01申请持续被接受，并由CIDR访问委员会评估其科学价值。 CIDR理事会由支持性IC的代表组成，是第二级审查机构，决定哪些项目可以使用CIDR设施。 该合同授予是为了支持遗传疾病研究中心（CIDR）项目1X 01 HG 013188 -01，阐明种族/民族差异的表观遗传机制， 胰腺癌，特别是使用来自多种族队列（MEC）的695例胰腺癌病例和800例年龄、性别和种族/种族匹配的对照的Illumina EPIC甲基化阵列进行全基因组基因分型。本实验是为了研究DNA甲基化中的种族/民族特异性差异是否 可以解释胰腺癌发病风险的差异。